DP-C-4

Target: DP-C-4 simultaneously targets EGFR and PARP proteins for dual degradation.

Binding site: It engages EGFR kinase and PARP catalytic domains through target-recognition ligands.

Mechanism of action: DP-C-4 is a CRBN-based dual-targeting PROTAC designed to degrade EGFR and PARP within the same cellular system. The compound combines target-recognition elements with a cereblon-recruiting ligand, enabling formation of productive ternary complexes between each target protein and the CRL4CRBN ubiquitin ligase machinery. This proximity-driven process promotes ubiquitination and proteasome-mediated depletion of both proteins. In research applications, DP-C-4 is useful for probing coordinated suppression of receptor tyrosine kinase signaling and DNA damage repair pathways, particularly when simultaneous degradation provides mechanistic advantages over single-target inhibition.

• PROTAC-Mediated Oncogene Degradation: DP-C-4 is utilized in research to selectively degrade oncogenic proteins, providing a powerful tool for studying cancer biology. By inducing the ubiquitination and subsequent proteasomal degradation of specific oncogenes, DP-C-4 helps elucidate the roles of these proteins in tumorigenesis.

• Targeted Degradation in Neurodegenerative Research: Researchers employ DP-C-4 to investigate the degradation of neurodegenerative disease-related proteins. This approach enables the study of pathogenic protein accumulation and its effects, potentially uncovering novel therapeutic targets for diseases like Alzheimer's and Parkinson's.

• PROTAC-Based Signal Pathway Analysis: DP-C-4 facilitates the exploration of cellular signaling pathways by enabling the targeted degradation of key signaling proteins. This application aids in dissecting complex signal transduction networks, offering insights into cellular responses and potential intervention points in various biological processes.

• Therapeutic Target Validation: In drug discovery, DP-C-4 is instrumental in validating potential therapeutic targets through targeted protein degradation. By selectively eliminating proteins of interest, researchers can assess the downstream effects and viability of these targets for therapeutic intervention.